SCHEMBL2511903

SCHEMBL2511903

COC(=O)C1=C2c3ccccc3C(=O)N2CCC1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CASP3 P42574 2/20 0.42
SLC6A3 Q01959 5/20 0.42
SLC6A2 P23975 4/20 0.42
SLC6A4 P31645 1/20 0.42
CHRM2 P08172 2/20 0.40
CHRM4 P08173 2/20 0.40
CHRM5 P08912 2/20 0.40
CHRM1 P11229 2/20 0.40
CHRM3 P20309 2/20 0.40
CDC25A P30304 1/20 0.39
CDC25B P30305 1/20 0.39
POLB P06746 2/20 0.39
MEN1 O00255 1/20 0.39
KMT2A Q03164 1/20 0.39
SMN1; SMN2 Q16637 2/20 0.38
HSD17B10 Q99714 2/20 0.38
ALDH1A1 P00352 1/20 0.38
MAPK1 P28482 2/20 0.37
ALOX15 P16050 1/20 0.37
HTT P42858 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12228125 0.92 CASP3 (0.43) CASP3SLC6A3SLC6A2SLC6A4CHRM2
SCHEMBL12202083 0.85 CASP3 (0.45) CASP3CHRM2CHRM4CHRM5CHRM1
SCHEMBL2516651 0.82 POLB (0.44) POLBKMT2ASMN1; SMN2HSD17B10ALDH1A1
SCHEMBL12202091 0.74 NPC1 (0.45) CASP3POLBSMN1; SMN2ALDH1A1HTT
SCHEMBL12202124 0.73 BCAT2 (0.41) POLBMEN1KMT2ASMN1; SMN2HSD17B10
SCHEMBL3522804 0.72 PGR (0.42) SLC6A3SLC6A2MEN1KMT2AALDH1A1
SCHEMBL3521856 0.72 DRD2 (0.41) SLC6A3SLC6A2MEN1KMT2AALDH1A1
SCHEMBL3520212 0.71 TP53 (0.46) SLC6A3POLBMEN1KMT2AALDH1A1
SCHEMBL12228324 0.71 TSHR (0.39) CASP3CDC25ACDC25BMEN1KMT2A
SCHEMBL24429208 0.69 NPC1 (0.48) CASP3CDC25BPOLBMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8034939-B2 1-{3-H-imidazo[4,5-c]pyridin-2-yl}-3,4-dihydro-2H-pyrido[2,1-a] isoindole-6-one; anticarcinogenic agent: solid tumor and leukemia; neurodegenerative diseases: Alzheimer's and Huntington's diseases AVENTIS PHARMA S.A.. (FR) 2011-10-11 US disclosed
US-20080119507-A1 Novel Isoindole Derivatives, Compositions Containing Same, Preparation Thereof and Pharmaceutical Uses Thereof in Particular as Inhibitors of Chaperone Protein HSP90 Activities AVENTIS PHARMA S.A. (FR) 2008-05-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080119507-A1 Novel Isoindole Derivatives, Compositions Containing Same, Preparation Thereof and Pharmaceutical Uses Thereof in Particular as Inhibitors of Chaperone Protein HSP90 Activities HSP90B1, HSP90AB2P, HSP90AB1 CASP3 4005/4885SLC6A3 3049/4885SLC6A2 2377/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.